NASDAQ: PASG

Passage Bio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PASG. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Passage Bio, Inc. (NASDAQ: PASG) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.

What Passage Bio, Inc. does

The company is a clinical-stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, is a gene replacement therapy that uses an AAV1 capsid to deliver a functional granulin gene to the brain to treat frontotemporal dementia caused by progranulin deficiency, which currently has no approved disease-modifying therapies. The company is also exploring PBFT02's potential in additional neurodegenerative conditions including other forms of frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease.

Summarized from Passage Bio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for PASG are available in Oxford Ledge.
Open PASG in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-29

Most recent filed transactions — June 2026:

2026-06-2910% OwnerPurchase50,055$206.1K
2026-05-21DirectorDirector Stock Option (right to buy)Award10,539—
2026-05-21DirectorDirector Stock Option (right to buy)Award10,539—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

CITADEL ADVISORS LLC2,886,125$4.31M+16242.7%
Lynx1 Capital Management LP673,759$3.29M+8.0%
Vestal Point Capital, LP305,000$2.39M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-03-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-07-20Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-10-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Remix to go public in reverse merger with once high-flying Passage Bio
BioPharma Dive2026-06-25
Remix does reverse merger with Passage Bio for mRNA degrader
Endpoints News2026-06-24
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PASG and 5,000+ tickers.

Create a free account — keep PASG

For your agent

GET /api/data?ticker=PASG

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt